Key Highlights
- Net loss was USD 5.9 million, against USD 1.5 million a year earlier.
- Research and development expense reached USD 5.0 million versus USD 1.4 million.
- Loss per share was USD 7.33 versus USD 1.83.
- Cash stood at USD 9.2 million on September 30, before the October IPO.
A single trial explains most of the jump in costs at Retension Pharmaceuticals (NASDAQ:RTSN). The company, based in Falls Church, Virginia, has no Revenue yet and is at the clinical stage, developing medicines for hypertension and other cardiovascular diseases. RTN-001 is its only product candidate. Third-quarter 2026 Research and Development expense was USD 5,016,602 versus USD 1,365,256, and the company says the Phase 2b trial is the largest component of that spending.
General and administrative expense was USD 990,759 versus USD 299,574, and total operating expenses were USD 6,007,361 versus USD 1,664,830. The net loss came to USD 5,918,084 against USD 1,475,814, or USD 7.33 per share versus USD 1.83.
The Drug Candidate and Its Licence
RTN-001 is a once-daily, oral, small-molecule phosphodiesterase-5 inhibitor. It is in a randomized, double-blind, placebo-controlled Phase 2b trial testing several doses in adults whose hypertension is uncontrolled. Initial data are guided for the first half of 2027, and a Phase 3 trial is planned.
Its Subsidiary holds an exclusive sublicense from Redux Therapeutics under a November 2023 agreement. The company took on Redux's milestone and Royalty obligations to Kadmon, a Sanofi subsidiary. Royalties are described as a low-teens share of net sales and of sublicensing revenue. The company states that it has no Lease obligations.
The Nine Months and Cash Burn
Over nine months, the net loss was USD 13,443,134 versus USD 3,361,487, or USD 16.65 per share versus USD 4.17. Research and development expense was USD 11,219,240 versus USD 2,542,254, general and administrative expense was USD 2,574,495 versus USD 1,231,791, and interest income was USD 351,457 versus USD 412,558.
Operating activities used about USD 9.4 million of cash, compared with about USD 2.5 million. Financing used about USD 0.3 million, mostly offering costs paid in connection with the initial public offering, while the prior-year period brought in about USD 13.8 million from Series B convertible preferred stock. There was no investing activity in either period.
Balance Sheet and Points to Follow
Cash and cash equivalents were USD 9,190,083 versus USD 18,901,024 at year-end 2025, and total Assets were USD 14,148,496. Deferred offering costs were USD 2,487,892, Accounts Payable were USD 3,886,011 and accrued expenses were USD 2,772,818. Total liabilities were USD 6,658,829, convertible preferred stock was carried at USD 28,153,769 and the accumulated Deficit was USD 21,758,323. The year-end 2025 Balance Sheet is shown as restated.
Weighted-average common shares were 807,894 for the quarter versus 805,154. Series A Preferred Shares outstanding were 1,771,415 and Series B were 2,002,704, with Liquidation preferences of USD 11,000,000 and USD 20,000,000.
The initial public offering closed in October 2026. The company states that its existing cash plus net IPO proceeds should meet expected needs for at least twelve months from the date of the financial statements, and that it will still need substantial extra funding further out. Points to follow are Phase 2b enrollment, spending levels and how the IPO proceeds are used.





_11_19_2026_19_57_40_035532.jpg)
Please wait processing your request...